Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Efficacy and Safety of Tenapanor in Patients with Hyperphosphatemia Receiving Maintenance Hemodialysis: A Randomized Phase 3 Trial.

Block GA, Rosenbaum DP, Yan A, Chertow GM.

J Am Soc Nephrol. 2019 Apr;30(4):641-652. doi: 10.1681/ASN.2018080832. Epub 2019 Mar 7.

PMID:
30846557
2.

Inhibition of sodium/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability.

King AJ, Siegel M, He Y, Nie B, Wang J, Koo-McCoy S, Minassian NA, Jafri Q, Pan D, Kohler J, Kumaraswamy P, Kozuka K, Lewis JG, Dragoli D, Rosenbaum DP, O'Neill D, Plain A, Greasley PJ, Jönsson-Rylander AC, Karlsson D, Behrendt M, Strömstedt M, Ryden-Bergsten T, Knöpfel T, Pastor Arroyo EM, Hernando N, Marks J, Donowitz M, Wagner CA, Alexander RT, Caldwell JS.

Sci Transl Med. 2018 Aug 29;10(456). pii: eaam6474. doi: 10.1126/scitranslmed.aam6474.

3.

An Evaluation of the Pharmacodynamics, Safety, and Tolerability of the Potassium Binder RDX7675.

Pitt B, Zann V, Roe C, Jacobs JW, Davidson JP, Dowd C, Kumaraswamy P, Lin F, Korner P, Blanks RC, Rosenbaum DP.

J Clin Pharmacol. 2018 Apr 12. doi: 10.1002/jcph.1102. [Epub ahead of print]

PMID:
29645278
4.

The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemia.

Block GA, Rosenbaum DP, Yan A, Greasley PJ, Chertow GM, Wolf M.

Nephrol Dial Transplant. 2019 Feb 1;34(2):339-346. doi: 10.1093/ndt/gfy061.

5.

Pharmacodynamics, Safety, and Tolerability of the NHE3 Inhibitor Tenapanor: Two Trials in Healthy Volunteers.

Rosenbaum DP, Yan A, Jacobs JW.

Clin Drug Investig. 2018 Apr;38(4):341-351. doi: 10.1007/s40261-017-0614-0.

6.

Palatability and physical properties of potassium-binding resin RDX7675: comparison with sodium polystyrene sulfonate.

Zann V, McDermott J, Jacobs JW, Davidson JP, Lin F, Korner P, Blanks RC, Rosenbaum DP.

Drug Des Devel Ther. 2017 Sep 6;11:2663-2673. doi: 10.2147/DDDT.S143461. eCollection 2017.

7.

Tenapanor administration and the activity of the H+ -coupled transporter PepT1 in healthy volunteers.

Johansson S, Rosenbaum DP, Palm J, Stefansson B, Knutsson M, Lisbon EA, Hilgendorf C.

Br J Clin Pharmacol. 2017 Sep;83(9):2008-2014. doi: 10.1111/bcp.13313. Epub 2017 May 31.

8.

Effect of Food Intake on the Pharmacodynamics of Tenapanor: A Phase 1 Study.

Johansson SA, Knutsson M, Leonsson-Zachrisson M, Rosenbaum DP.

Clin Pharmacol Drug Dev. 2017 Sep;6(5):457-465. doi: 10.1002/cpdd.341. Epub 2017 Mar 24.

9.

Effects of Tenapanor on Cytochrome P450-Mediated Drug-Drug Interactions.

Johansson S, Rosenbaum DP, Ahlqvist M, Rollison H, Knutsson M, Stefansson B, Elebring M.

Clin Pharmacol Drug Dev. 2017 Sep;6(5):466-475. doi: 10.1002/cpdd.346. Epub 2017 Mar 16.

10.

Tenapanor Treatment of Patients With Constipation-Predominant Irritable Bowel Syndrome: A Phase 2, Randomized, Placebo-Controlled Efficacy and Safety Trial.

Chey WD, Lembo AJ, Rosenbaum DP.

Am J Gastroenterol. 2017 May;112(5):763-774. doi: 10.1038/ajg.2017.41. Epub 2017 Feb 28.

11.

Effect of Tenapanor on Serum Phosphate in Patients Receiving Hemodialysis.

Block GA, Rosenbaum DP, Leonsson-Zachrisson M, Åstrand M, Johansson S, Knutsson M, Langkilde AM, Chertow GM.

J Am Soc Nephrol. 2017 Jun;28(6):1933-1942. doi: 10.1681/ASN.2016080855. Epub 2017 Feb 3.

12.

Preclinical and Healthy Volunteer Studies of Potential Drug-Drug Interactions Between Tenapanor and Phosphate Binders.

Johansson S, Leonsson-Zachrisson M, Knutsson M, Spencer AG, Labonté ED, Deshpande D, Kohler J, Kozuka K, Charmot D, Rosenbaum DP.

Clin Pharmacol Drug Dev. 2017 Sep;6(5):448-456. doi: 10.1002/cpdd.307. Epub 2016 Oct 26.

13.

A phase 1 study of the safety, tolerability, pharmacodynamics, and pharmacokinetics of tenapanor in healthy Japanese volunteers.

Johansson S, Rosenbaum DP, Knutsson M, Leonsson-Zachrisson M.

Clin Exp Nephrol. 2017 Jun;21(3):407-416. doi: 10.1007/s10157-016-1302-8. Epub 2016 Jul 1.

14.

Effect of Tenapanor on Interdialytic Weight Gain in Patients on Hemodialysis.

Block GA, Rosenbaum DP, Leonsson-Zachrisson M, Stefansson BV, Rydén-Bergsten T, Greasley PJ, Johansson SA, Knutsson M, Carlsson BC.

Clin J Am Soc Nephrol. 2016 Sep 7;11(9):1597-605. doi: 10.2215/CJN.09050815. Epub 2016 Jun 23.

15.

Intestinal inhibition of the Na+/H+ exchanger 3 prevents cardiorenal damage in rats and inhibits Na+ uptake in humans.

Spencer AG, Labonte ED, Rosenbaum DP, Plato CF, Carreras CW, Leadbetter MR, Kozuka K, Kohler J, Koo-McCoy S, He L, Bell N, Tabora J, Joly KM, Navre M, Jacobs JW, Charmot D.

Sci Transl Med. 2014 Mar 12;6(227):227ra36. doi: 10.1126/scitranslmed.3007790.

16.

University of Illinois at Chicago's interdisciplinary center for research on violence: changing systems to prevent violence in Chicago and beyond.

Schewe P, Bell CC, Bennett L, Goldstein PJ, Gordon R, Mattaini M, O'Brien P, Riger S, Risser HJ, Rosenbaum DP, Schuck AM, Simmons B, Ullman SE.

Violence Against Women. 2011 Sep;17(9):1176-93. doi: 10.1177/1077801211419325. Epub 2011 Sep 13.

PMID:
21914681
17.

Posterior fossa craniotomy for trapped fourth ventricle in shunt-treated hydrocephalic children: long-term outcome.

Udayakumaran S, Biyani N, Rosenbaum DP, Ben-Sira L, Constantini S, Beni-Adani L.

J Neurosurg Pediatr. 2011 Jan;7(1):52-63. doi: 10.3171/2010.10.PEDS10139.

PMID:
21194288
18.

Recanting of substance use reports in a longitudinal prevention study.

Fendrich M, Rosenbaum DP.

Drug Alcohol Depend. 2003 Jun 5;70(3):241-53.

PMID:
12757962
19.

Sevelamer, a phosphate-binding polymer, is a non-absorbed compound.

Plone MA, Petersen JS, Rosenbaum DP, Burke SK.

Clin Pharmacokinet. 2002;41(7):517-23.

PMID:
12083979
20.

Effect of RenaGel, a non-absorbable, cross-linked, polymeric phosphate binder, on urinary phosphorus excretion in rats.

Rosenbaum DP, Holmes-Farley SR, Mandeville WH, Pitruzzello M, Goldberg DI.

Nephrol Dial Transplant. 1997 May;12(5):961-4.

PMID:
9175050
21.

Absorption, distribution and excretion of GT31-104, a novel bile acid sequestrant, in rats and dogs after acute and subchronic administration.

Rosenbaum DP, Petersen JS, Ducharme S, Markham P, Goldberg DI.

J Pharm Sci. 1997 May;86(5):591-5.

PMID:
9145384
22.

Characteristics of students who bring weapons to school.

Bailey SL, Flewelling RL, Rosenbaum DP.

J Adolesc Health. 1997 Apr;20(4):261-70.

PMID:
9098729
23.

Long-term evaluation of drug abuse resistance education.

Ennett ST, Rosenbaum DP, Flewelling RL, Bieler GS, Ringwalt CL, Bailey SL.

Addict Behav. 1994 Mar-Apr;19(2):113-25.

PMID:
8036959
24.

Enantiomers of 7-(2,3-epoxypropoxy)actinomycin D as dual-action DNA-acting antitumor agents.

Sengupta SK, Rosenbaum DP, Sehgal RK, Almassian B, Blondin J.

J Med Chem. 1988 Aug;31(8):1540-7.

PMID:
3397991
25.

Synthesis and biological properties of actinomycin D chromophoric analogues substituted at carbon 7 with aziridine and cyclopropyl functions.

Sehgal RK, Almassian B, Rosenbaum DP, Zadrozny R, Sengupta SK.

J Med Chem. 1988 Apr;31(4):790-3.

PMID:
3162533
26.

Synthesis and biological properties of actinomycin D chromophoric analogues substituted at the 7-carbon with aziridine and aminopropoxy functions.

Sehgal RK, Almassian B, Rosenbaum DP, Zadrozny R, Sengupta SK.

J Med Chem. 1987 Sep;30(9):1626-31.

PMID:
3476754
27.

In vitro binding of mirex by mouse hepatocytes.

Rosenbaum DP, Charles AK.

J Toxicol Environ Health. 1986;17(4):385-93.

PMID:
3959119
28.

Uptake and disposition of mirex in hepatocytes and subcellular fractions in CD1 mouse liver.

Charles AK, Rosenbaum DP, Ashok L, Abraham R.

J Toxicol Environ Health. 1985;15(3-4):395-403.

PMID:
4032488

Supplemental Content

Loading ...
Support Center